264 filings
Page 2 of 14
8-K
dxffola101o ms
14 Aug 23
Other Events
8:00am
8-K
uttod1uzfk0 98td2v
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
nl0q inlxm
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
czsnu1px9s34z6a
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
ozzt8cl
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
nxzri3 t1
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
dkfd3ox9cw v4
12 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
ARS
fduqnbp
11 Apr 23
Annual report to shareholders
4:08pm
8-K
2j2jdene1tv5d nye5q
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
S-8
7q2z5ov4h0
14 Mar 23
Registration of securities for employees
5:16pm
S-8
bywwrwi6
14 Mar 23
Registration of securities for employees
5:15pm
8-K
rt1ob0 1th0pw
14 Mar 23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
7:32am
8-K
qfzppcw
7 Feb 23
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
4:20pm
8-K
menznzt71k
9 Jan 23
January 2023 Larimar Therapeutics Corporate Presentation
4:03pm
EFFECT
1pwhc6t00n
22 Nov 22
Notice of effectiveness
12:15am
CORRESP
yvnzo5rufu if0ct8pxh
18 Nov 22
Correspondence with SEC
12:00am